Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | NMT1 | P30419 | 12/20 | 0.42 |
| ▸ | MOGAT2 | Q3SYC2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MLNR | O43193 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963564 | 0.91 | KCNH2 (0.44) | KCNH2LMNAGAAALDH1A1NPSR1 | |
| SCHEMBL2484521 | 0.82 | KCNH2 (0.40) | KCNH2MOGAT2LMNAGAAALDH1A1 | |
| SCHEMBL22123904 | 0.81 | LMNA (0.47) | KCNH2LMNAGAANPSR1 | |
| SCHEMBL20573232 | 0.76 | MAOB (0.40) | LMNAALDH1A1 | |
| SCHEMBL7735405 | 0.76 | DAO (0.41) | LMNAALDH1A1 | |
| SCHEMBL23387596 | 0.76 | L3MBTL1 (0.47) | LMNAGAAALDH1A1NPSR1 | |
| SCHEMBL1714161 | 0.76 | AOC2 (0.39) | KCNH2LMNAALDH1A1NPSR1MLNR | |
| SCHEMBL17797595 | 0.75 | LMNA (0.38) | KCNH2LMNAGAAALDH1A1 | |
| SCHEMBL12453115 | 0.75 | DAO (0.43) | LMNAALDH1A1NPSR1 | |
| SCHEMBL30446884 | 0.75 | CA2 (0.57) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | ABBVIE INC. | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058335-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | CNR1, CNR2, OPRL1 | KCNH2 2728/4885NMT1 2225/4885MOGAT2 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.